Neuphoria Therapeutics Inc. Other Noncash Income (Expense)
Neuphoria Therapeutics Inc. (NEUP) reported Other Noncash Income (Expense) of -$102.61 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-09-18
- Neuphoria Therapeutics Inc. other noncash income (expense) for the quarter ending 2026-06-30 was $12.05K.
- Neuphoria Therapeutics Inc. other noncash income (expense) for the quarter ending 2026-03-31 was $0.00.
- Neuphoria Therapeutics Inc. other noncash income (expense) for the quarter ending 2025-12-31 was -$87.27K.
- Neuphoria Therapeutics Inc. other noncash income (expense) for the quarter ending 2025-09-30 was -$27.39K.
- Neuphoria Therapeutics Inc. other noncash income (expense) for fiscal 2026 was -$102.61K.
- Neuphoria Therapeutics Inc. other noncash income (expense) for fiscal 2025 was -$114.36K.
- Neuphoria Therapeutics Inc. other noncash income (expense) for fiscal 2024 was -$113.50K.
- Neuphoria Therapeutics Inc. other noncash income (expense) for fiscal 2023 was -$115.12K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.05K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $12.05K derived: sum of 2 quarters · filed 2026-09-18 | -$75.22K derived: sum of 3 quarters · filed 2026-09-18 | -$102.61K 10-K · filed 2026-09-18 |
| 2026-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$87.27K derived: sum of 2 quarters · filed 2026-05-15 | -$114.66K 10-Q · filed 2026-05-15 | -$137.26K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | -$87.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$114.66K 10-Q · filed 2026-02-17 | -$137.26K derived: sum of 3 quarters · filed 2026-09-18 | -$162.57K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | -$27.39K 10-Q · filed 2025-11-14 | -$49.99K derived: sum of 2 quarters · filed 2026-09-18 | -$75.30K derived: sum of 3 quarters · filed 2026-09-18 | -$122.23K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | -$22.60K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$47.91K derived: sum of 2 quarters · filed 2026-09-18 | -$94.83K derived: sum of 3 quarters · filed 2026-09-18 | -$114.36K 10-K · filed 2026-09-18 |
| 2025-03-31 | -$25.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$72.23K derived: sum of 2 quarters · filed 2026-05-15 | -$91.76K 10-Q · filed 2026-05-15 | -$116.66K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$46.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$66.46K 10-Q · filed 2026-02-17 | -$91.35K derived: sum of 3 quarters · filed 2026-02-17 | -$131.98K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$19.53K 10-Q · filed 2025-11-14 | -$44.42K derived: sum of 2 quarters · filed 2025-11-14 | -$85.05K derived: sum of 3 quarters · filed 2025-11-14 | -$96.86K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$24.89K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$65.52K derived: sum of 2 quarters · filed 2025-09-29 | -$77.34K derived: sum of 3 quarters · filed 2025-09-29 | -$113.50K 10-K · filed 2025-09-29 |
| 2024-03-31 | -$40.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-20 | -$52.44K derived: sum of 2 quarters · filed 2025-05-20 | -$88.61K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | -$11.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | -$47.98K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | -$36.17K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$115.12K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |